T2 Biosystems, Inc. (TTOO)
USD 0.35
(2.88%)
USD 0.35
(2.88%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -49.66 Million USD | 15.05% |
| 2022 | -55.51 Million USD | -29.17% |
| 2021 | -42.97 Million USD | -3.91% |
| 2020 | -41.35 Million USD | 20.56% |
| 2019 | -52.05 Million USD | -15.45% |
| 2018 | -45.09 Million USD | 16.27% |
| 2017 | -53.85 Million USD | -5.85% |
| 2016 | -50.87 Million USD | -17.28% |
| 2015 | -43.38 Million USD | -41.4% |
| 2014 | -30.68 Million USD | -55.8% |
| 2013 | -19.69 Million USD | -34.39% |
| 2012 | -14.65 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -12.6 Million USD | -35.21% |
| 2024 Q2 | -9.57 Million USD | 24.01% |
| 2023 Q1 | -13.68 Million USD | -39.18% |
| 2023 Q4 | -9.31 Million USD | 31.51% |
| 2023 Q3 | -13.6 Million USD | -4.26% |
| 2023 Q2 | -13.05 Million USD | 4.65% |
| 2023 FY | -47.15 Million USD | 15.05% |
| 2022 Q2 | -15.01 Million USD | -1.09% |
| 2022 Q4 | -9.83 Million USD | 37.76% |
| 2022 FY | -55.51 Million USD | -29.17% |
| 2022 Q1 | -14.85 Million USD | -44.54% |
| 2022 Q3 | -15.8 Million USD | -5.2% |
| 2021 Q1 | -9.7 Million USD | -16.61% |
| 2021 Q4 | -10.27 Million USD | 15.83% |
| 2021 Q3 | -12.21 Million USD | -13.28% |
| 2021 FY | -42.97 Million USD | -3.91% |
| 2021 Q2 | -10.78 Million USD | -11.11% |
| 2020 FY | -41.35 Million USD | 20.56% |
| 2020 Q1 | -13.56 Million USD | -9.65% |
| 2020 Q2 | -8.83 Million USD | 34.82% |
| 2020 Q3 | -10.63 Million USD | -20.33% |
| 2020 Q4 | -8.32 Million USD | 21.78% |
| 2019 Q3 | -12.34 Million USD | 10.45% |
| 2019 FY | -52.05 Million USD | -15.45% |
| 2019 Q4 | -12.36 Million USD | -0.18% |
| 2019 Q2 | -13.78 Million USD | -1.67% |
| 2019 Q1 | -13.55 Million USD | 0.26% |
| 2018 Q3 | -9.17 Million USD | 15.73% |
| 2018 FY | -45.09 Million USD | 16.27% |
| 2018 Q1 | -11.43 Million USD | 20.4% |
| 2018 Q2 | -10.88 Million USD | 4.79% |
| 2018 Q4 | -13.59 Million USD | -48.18% |
| 2017 FY | -53.85 Million USD | -5.85% |
| 2017 Q1 | -13.14 Million USD | -1.84% |
| 2017 Q2 | -13.9 Million USD | -5.77% |
| 2017 Q3 | -12.43 Million USD | 10.55% |
| 2017 Q4 | -14.36 Million USD | -15.51% |
| 2016 Q1 | -12.72 Million USD | -10.2% |
| 2016 Q4 | -12.9 Million USD | -8.05% |
| 2016 Q3 | -11.94 Million USD | 10.21% |
| 2016 Q2 | -13.3 Million USD | -4.56% |
| 2016 FY | -50.87 Million USD | -17.28% |
| 2015 Q4 | -11.54 Million USD | -3.4% |
| 2015 Q2 | -10.52 Million USD | -3.67% |
| 2015 Q1 | -10.15 Million USD | -14.86% |
| 2015 FY | -43.38 Million USD | -41.4% |
| 2015 Q3 | -11.16 Million USD | -6.09% |
| 2014 Q1 | -6.9 Million USD | -22.49% |
| 2014 Q3 | -7.78 Million USD | -8.92% |
| 2014 Q4 | -8.83 Million USD | -13.5% |
| 2014 FY | -30.68 Million USD | -55.8% |
| 2014 Q2 | -7.14 Million USD | -3.5% |
| 2013 Q4 | -5.63 Million USD | -24.15% |
| 2013 FY | -19.69 Million USD | -34.39% |
| 2013 Q1 | -4.6 Million USD | 0.0% |
| 2013 Q2 | -4.91 Million USD | -6.74% |
| 2013 Q3 | -4.54 Million USD | 7.49% |
| 2012 FY | -14.65 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Bionano Genomics, Inc. | -215.24 Million USD | 76.927% |
| Prenetics Global Limited | -52.51 Million USD | 5.426% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -1042.752% |
| CareDx, Inc | -101.9 Million USD | 51.262% |
| Exact Sciences Corporation | -215.01 Million USD | 76.902% |
| Exagen Inc. | -22.83 Million USD | -117.472% |
| Inotiv, Inc. | -81.46 Million USD | 39.033% |
| Guardant Health, Inc. | -564.72 Million USD | 91.206% |
| Biodesix, Inc. | -41.34 Million USD | -20.13% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | -1814.876% |
| Precipio, Inc. | -7.62 Million USD | -551.759% |
| iSpecimen Inc. | -11.16 Million USD | -344.645% |
| Natera, Inc. | -446.24 Million USD | 88.871% |
| Aspira Women's Health Inc. | -18.85 Million USD | -163.442% |
| Standard BioTools Inc. | -76.6 Million USD | 35.164% |
| 23andMe Holding Co. | -321.35 Million USD | 84.545% |
| Castle Biosciences, Inc. | -67.97 Million USD | 26.94% |
| Personalis, Inc. | -109.93 Million USD | 54.825% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 48.988% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | -353.416% |
| OpGen, Inc. | -15.68 Million USD | -216.564% |
| Myriad Genetics, Inc. | -123.7 Million USD | 59.851% |
| ICON Public Limited Company | 956.15 Million USD | 105.194% |
| NeoGenomics, Inc. | -107.73 Million USD | 53.902% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -1042.752% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 104.527% |
| RadNet, Inc. | 98.69 Million USD | 150.32% |
| MDxHealth SA | -27.32 Million USD | -81.74% |
| Psychemedics Corporation | -2.92 Million USD | -1600.24% |
| Illumina, Inc. | -1.06 Billion USD | 95.354% |
| Check-Cap Ltd. | -19.28 Million USD | -157.5% |
| Twist Bioscience Corporation | -220.83 Million USD | 77.51% |
| DarioHealth Corp. | -56.18 Million USD | 11.613% |
| Fulgent Genetics, Inc. | -72.69 Million USD | 31.682% |
| Sera Prognostics, Inc. | -39.82 Million USD | -24.718% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | -372.058% |
| OPKO Health, Inc. | -157.02 Million USD | 68.371% |
| Medpace Holdings, Inc. | 336.82 Million USD | 114.745% |
| Neogen Corporation | 58.66 Million USD | 184.66% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | -382.964% |
| Prenetics Global Limited | -52.51 Million USD | 5.426% |
| Mainz Biomed B.V. | -26.64 Million USD | -86.394% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -522.884% |
| Trinity Biotech plc | -27.04 Million USD | -83.635% |
| Neuronetics, Inc. | -30.55 Million USD | -62.545% |
| Sotera Health Company | 276.69 Million USD | 117.949% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -522.884% |